The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.

At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.

Inclusion Criteria:

• Having diffuse diabetic macular edema persisted at least 1 month
• No intravitreal injection in last 3 months.
• No retinal laser photocoagulation in last 6 months
• Not have any other macular disease causing macular edema

Exclusion Criteria:

• Having ischemic macula
• Intravitreal injection in last 3 months.
• Retinal laser photocoagulation in last 6 months
• Have any other macular disease causing macular edema